5-methyl-5H-pyrimido[5,4-b]indol-4-amine | 1338368-60-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: 5-methyl-5H-pyrimido[5,4-b]indol-4-amine
• 英文别名: 4-amino5-methyl-5H-pyrimido[5,4-b]indole；5-Methylpyrimido[5,4-b]indol-4-amine
• CAS: 1338368-60-7
• 化学式: C₁₁H₁₀N₄
• 分子量: 198.227
• InChiKey: LBXWWXLWVSDRRD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  15
• 可旋转键数：
  0
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.09
• 拓扑面积：
  56.7
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  3-amino-1H-indole-2-carbonitrile 以 N,N-二甲基甲酰胺 为溶剂， 反应 1.5h， 生成 5-methyl-5H-pyrimido[5,4-b]indol-4-amine
  参考文献：
  名称：

  Exploring Kinase Inhibition Properties of 9H-pyrimido[5,4-b]- and [4,5-b]indol-4-amine Derivatives

  摘要：

  我们先前强调了6,5,6-融合三环类4-氨基喹唑啉作为激酶抑制剂在微摩尔到纳摩尔范围内的IC50值的兴趣。为了生成化学库，使用甲酰胺介导的氰基胺前体的环化反应在微波辐射下进行，采用环保的方法。为了更深入地探索这种三环骨架的药理学兴趣，中心的五元环，即噻吩或呋喃，被替换为吡咯，以制备受到harmine启发的9H-嘧啶并[5,4-b]-和[4,5-b]吲哚-4-胺衍生物。最终产品的抑制效力被测定对四种蛋白激酶（CDK5/p25、CK1δ/ε、GSK3α/β和DYRK1A）。结果，我们已经确定了有前途的化合物，靶向CK1δ/ε和DYRK1A，显示微摩尔和亚微摩尔的IC50值。

  DOI：

  10.3390/ph13050089

文献信息

• [EN] PYRIDO [3',2' :4,5] THIENO [3, 2-D] PYRIMIDIN- 4 - YLAMINE DERIVATIVES AND THEIR THERAPEUTICAL USE<br/>[FR] DÉRIVÉS DE PYRIDO[3',2':4,5]THIÉNO[3,2-D]PYRIMIDIN-4-YLAMINE ET LEUR UTILISATION THÉRAPEUTIQUE
  申请人：BAELL JONATHAN BAYLDON

  公开号：WO2012131297A1

  公开（公告）日：2012-10-04

  The present invention pertains generally to the field of therapeutic compounds, and more specifically to certain fused triaryl amine compounds of the following formula (for convenience, collectively referred to herein as "FTA compounds"), which, inter alia, inhibit LIM kinase (LIMK) activity. The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit LIMK activity, and in the treatment of diseases and conditions that are mediated by LIMK, that are ameliorated by the inhibition of LIMK activity, etc., including proliferative conditions such as cancer (e.g., breast cancer, prostate cancer, melanoma, glioma, etc.), as well as vasodilation (including, e.g., hypertension, angina, cerebral vasospasm, and ischemia following subarachnoid hemorrhage), neurodegenerative disorders, atherosclerosis, fibrosis, and inflammatory diseases (including, e.g., Crohn's disease and chronic obstructive pulmonary disease (COPD)), and glaucoma (also known as ocular hypertension).

  本发明一般涉及治疗化合物领域，更具体地涉及以下公式的某些融合三芳基胺化合物（为方便起见，统称为“FTA化合物”），该化合物等等可以抑制LIM激酶（LIMK）活性。本发明还涉及包含这些化合物的药物组合物，以及利用这些化合物和组合物在体内和体外抑制LIMK活性，以及治疗由LIMK介导，通过抑制LIMK活性得到改善等疾病和症状的用途，包括增生性疾病，如癌症（如乳腺癌、前列腺癌、黑色素瘤、胶质瘤等），以及血管扩张（包括高血压、心绞痛、脑血管痉挛和蛛网膜下腔出血后缺血等）、神经退行性疾病、动脉硬化、纤维化和炎症性疾病（如克罗恩病和慢性阻塞性肺病（COPD）），以及青光眼（又称眼高压）等。
• Exploring Kinase Inhibition Properties of 9H-pyrimido[5,4-b]- and [4,5-b]indol-4-amine Derivatives
  作者：Yvonnick Loidreau、Carole Dubouilh-Benard、Marie-Renée Nourrisson、Nadège Loaëc、Laurent Meijer、Thierry Besson、Pascal Marchand

  DOI：10.3390/ph13050089

  日期：——

  We previously highlighted the interest in 6,5,6-fused tricyclic analogues of 4-aminoquinazolines as kinase inhibitors in the micromolar to the nanomolar range of IC50 values. For the generation of chemical libraries, the formamide-mediated cyclization of the cyanoamidine precursors was carried out under microwave irradiation in an eco-friendly approach. In order to explore more in-depth the pharmacological interest in such tricyclic skeletons, the central five member ring, i.e., thiophène or furan, was replaced by a pyrrole to afford 9H-pyrimido[5,4-b]- and [4,5-b]indol-4-amine derivatives inspired from harmine. The inhibitory potency of the final products was determined against four protein kinases (CDK5/p25, CK1δ/ε, GSK3α/β, and DYRK1A). As a result, we have identified promising compounds targeting CK1δ/ε and DYRK1A and displaying micromolar and submicromolar IC50 values.

  我们先前强调了6,5,6-融合三环类4-氨基喹唑啉作为激酶抑制剂在微摩尔到纳摩尔范围内的IC50值的兴趣。为了生成化学库，使用甲酰胺介导的氰基胺前体的环化反应在微波辐射下进行，采用环保的方法。为了更深入地探索这种三环骨架的药理学兴趣，中心的五元环，即噻吩或呋喃，被替换为吡咯，以制备受到harmine启发的9H-嘧啶并[5,4-b]-和[4,5-b]吲哚-4-胺衍生物。最终产品的抑制效力被测定对四种蛋白激酶（CDK5/p25、CK1δ/ε、GSK3α/β和DYRK1A）。结果，我们已经确定了有前途的化合物，靶向CK1δ/ε和DYRK1A，显示微摩尔和亚微摩尔的IC50值。